Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2024-03-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事2023年度述职报告（耿小平）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. It covers the director's activities, attendance at meetings, independent opinions on various company matters, committee work, on-site inspections, investor protection efforts, and training during the 2023 fiscal year. The content is focused on governance and oversight rather than financial results or earnings. It is not a brief announcement or a certification but a substantive report on the director's duties and contributions over the year. This fits best under Board/Management Information (MANG), which includes announcements and reports related to board members and senior management activities.
2024-03-27 Chinese
独立董事2023年度述职报告（陈飞虎）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. It covers the director's activities, attendance at board and shareholder meetings, independent opinions on various company matters, committee work, on-site inspections, investor protection efforts, and training during the year 2023. The content focuses on governance, oversight, and compliance with laws and regulations, which aligns with a Board/Management Information report rather than a full annual report or audit report. The document length is under 5,000 characters and is a comprehensive narrative of the director's duties and opinions, not a financial statement or earnings release. Therefore, the best classification is Board/Management Information (MANG).
2024-03-27 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the use of idle self-owned funds for cash management. It details the board meeting resolutions, investment scope, risk control measures, and approvals related to the cash management plan. The document is relatively short (2185 characters) and focuses on informing shareholders and the public about the company's decision to invest idle funds in low-risk financial products. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. Instead, it is an announcement about a capital management activity, specifically the use of idle funds for cash management. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including cash management activities.
2024-03-27 Chinese
关于选举监事会主席的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of the chairman of the supervisory board (监事会主席) of 安徽安科生物工程（集团）股份有限公司. It includes details about the meeting date, the resolution passed, and the biography of the elected chairman. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results from a general meeting, and no regulatory certifications. The content is about a management/board change, specifically the election of a supervisory board chairman, which falls under Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a report or a presentation but a management information announcement.
2024-03-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the ninth meeting of the eighth Supervisory Board of Anhui Anke Biotechnology (Group) Co., Ltd. It includes approvals of the 2023 Supervisory Board Work Report, 2023 Financial Final Accounts Report, 2023 Annual Report and its summary, profit distribution plan, internal control self-evaluation report, and other governance matters. The document states that these reports and proposals will be submitted to the 2023 Annual General Meeting for approval. The document is relatively short (3570 characters) and serves as a meeting resolution announcement rather than the full annual report or financial statements themselves. It also includes voting results and governance decisions but is primarily a meeting resolution announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as the full Annual Report (10-K) or a Declaration of Voting Results (DVA) since it is not the official voting result announcement but a meeting resolution notice.
2024-03-27 Chinese
关于召开2023年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of Anhui Anke Biotechnology (Group) Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and proxy forms. The document does not contain financial statements or detailed financial analysis but rather focuses on the logistics and agenda of the AGM. It is not the annual report itself, nor is it a voting results announcement or proxy solicitation material. Given the content and purpose, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM.
2024-03-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.